AbbVie hepatitis C cocktail succeeds in late-stage study

Reuters Health Information: AbbVie hepatitis C cocktail succeeds in late-stage study

AbbVie hepatitis C cocktail succeeds in late-stage study

Last Updated: 2015-06-24

By Reuters Staff

(Reuters) - AbbVie Inc said on Wednesday that its all oral hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with ribavirin against the most common form of the disease (genotype 1b), according to data from a late-stage study.

Viekira Pak, a combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir, was approved in December 2014 for use as both a standalone treatment and in tandem with ribavirin, a broad-spectrum antiviral approved in 1998.

All the patients in the study showed a sustained response to Viekira Pak as a standalone treatment after 12 weeks of treatment, AbbVie said.

The late-stage study on which the U.S. Food and Drug Administration based its decision to approve Viekira Pak in December showed it cured 91-100% of all patients with the infection.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.